A pre-diabetes case concerning metformin assumption to avoid progression to full disease

Main Article Content

Franco Pavese

Abstract

Pre-diabetes is commonly considered a preliminary form of (full) diabetes, which can be delayed to occur later in life by the prescription of daily administration of metformin in addition to personal training through diet and other glucose-reducing general rules.


The Author found himself in such a situation after an infection during a foreign travel, damaging his pancreatic functions and bringing his glucose level quite above 125 mg/dL. He was immediately prescribed a diet and the administration of a brand of metformin. It was assumed for about 8 years until this brand of metformin became commercially unavailable: his previous publications on this subject matter have shown how glucose level was subsequently maintained in the range below 125 mg/dL without exceptions, according to frequent home tests and also according to an annual professional test.


Recently, the author had to change the kind of metformin due to the lack of the former, but he had evidence of some of the problems that are indicated in the literature as typical of this assumption, namely diarrheal. This fact prompted the author to also check whether, in his case, the assumption of metformin was possibly non-strictly needed.


The present case is reported here with the results of a test period of a ≈5 months without interruption, after a month where alternated weeks with and without assumption were spent for a quick observation of the possible differences in the effects. This kind of case strictly requires the use of the methodology the author has developed to perform the home tests: it consists mainly of an extremely careful and frequent recalibration of the tools used in the home tests, strips and testers. He is assuming to be a valid and necessary precaution for studying these types of cases, developed during his very long professional career in Measurement Science and specifically in Metrology.


The results of the study on this case are expected to allow for a forecast over the longer term without need to get a statistics longer than a few months, highlighting two main issues: when combined with a healthy lifestyle, metformin can help patients maintain a stable blood glucose level, even below 100 mg/dL; additionally, the administration of metformin was not necessarily needed to avoid an increase in blood glucose levels above 125 mg/dL over time.


Not being a medical doctor, the author cannot make a general statement about the lack of need for assumption of metformin. The author also found in his case that assumed metformin immediately brought the glucose level even below 100 mg/dL, which can be considered a non-necessary though safer situation—this was also an occasional case for the previous metformin type. On the other hand, this may also indicate that a correct diet and personal training may be sufficient to prevent pre-diabetes.

Article Details

How to Cite
PAVESE, Franco. A pre-diabetes case concerning metformin assumption to avoid progression to full disease. Medical Research Archives, [S.l.], v. 14, n. 5, may 2026. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/7211>. Date accessed: 02 june 2026. doi: https://doi.org/10.18103/mra.v14i5.7211.
Section
Research Articles

References

1. Pavese F. Findings from a Metrological Analysis of Test-Strip Use in Diabetes Home-Care Control: A Confirmation. Clinical Cases in Medicine. Medtext Publications. 2022;2(Article 1016): 24-26. ISSN: 2770-2359.
2. Pavese F. A long-term case study on marginal diabetes: demonstrating the need for effective calibration of home test devices. Medical Research Archives [S.l.]. 2024;12(9):1–7. ISSN 2375-1924. Available at: https://esmed.org/MRA/mra/article/view/5873.
3. Pavese F. A testing/metrological look at the accuracy of glucose strip measurements in home care for marginal diabetes, for mitigating diabetic kidney disease. J. of Nephrology. 2022;35:1565-1569. Available at: https://doi.org/10.1007/s40620-021-01224-6 . With Supplementary Information: suppl-info-40620_2021_1224_MOESM1_ESM.pdf.
4. Pavese F. Further Problems in Tester Calibration and Control Solution in Home Monitoring of Pre-Diabetes. Medical Research Archives. 2025;13(6) 1–5. Available at: https://doi.org/10.18103/mra.v13i6.6516 .
5. Pavese F. A Note on the Urgent Need for Consistent Regulation of the Procedure for Determination of Reliable Pre-Diabetes Diagnosis, Namely in The Next Edition of the ISO 15197. Medical Research Archives. 2025;13(8):1–10.
6. Pavese F. A Case of Pre-Diabetes Showing Interesting Features when Monitored by Home Tests with Sound Measurement Science Tools. Mega J Case Rep. 2025;8(11):1–5. Open Access.
7. Brake J. Sustained release metformin where standard metformin is not tolerated. Journal of Diabetes Nursing 2007;11:32–36.
8. Duggal N. What to Know About Stopping Metformin: Side Effects, Risks, and How to Stop, October 24, 2024. Available at: https://www.healthline.com/health/stopping-metformin#summary
9. Zeshui Yu, Pharm D, Chen Jiang, MS, Zheng Zeng, MS, Hui Wang, Yuqing Chen, Lirong Wang The Pattern of Metformin Discontinuation and Reinitiation in US adults with Prediabetes. MedRxiv Dec. 2 2025. Available at: https://doi.org/10.64898/2025.11.29.25341250.
10. Yang Aimin, Shi Mai, Wu Hongjiang, Lau Eric SH., Johnny TK, Cheung, Xinge Zhang, Baoqi Fan, Tingting Chen, Alice PS Kong, Andrea OY, Luk Ronald CW, Ma Juliana CN, Chowa Elaine, Clinical outcomes following discontinuation of metformin in patients with type 2 diabetes and advanced chronic kidney disease in Hong Kong: a territory-wide, retrospective cohort and target trial emulation study. eClinicalMedicine 2024;71:102568. Available at: https://doi.org/10.1016/j.eclinm.2024.102568 .
11. Persaud N. Study Investigates Whether and When to Stop Metformin in Advanced CKD. Available at: https://www.empr.com/news/stud-investigates-whether
ENDNOTES
a. The concept of “evidence”, today preferred to “experience” in medicine, is generally ignored in metrology, where correctness of assumptions must be verified from the results of measurements, as the highest possible level available to check their “truth”.
c. It was more or less the same for all trip batches and testers, the indication being higher than the correct glucose level except very few exceptions, and typically around ≈ +10 mg/dL— this paper considers only capillary (full) blood: when considered, plasma is always specified and converted to capillary blood.